Advancing Gene Therapies And Curative Health Care Through Value-Based Payment Reform

News Update

Advancing Gene Therapies And Curative Health Care Through Value-Based Payment Reform

Date

October 31, 2017

Read more from Spark Therapeutics CEO Jeff Marrazzo, bluebird bio CEO Nick Leschly is CEO, Duke-Margolis deputy director for policy Gregory Daniel and director Mark McClellan on the Health Affairs blog.

The companies are members of and provide support to a value-based payment consortium convened by Duke-Margolis.